Histamine, Histamine Receptors, and Their Role in Immunomodulation: an Updated Systematic Review

Total Page:16

File Type:pdf, Size:1020Kb

Histamine, Histamine Receptors, and Their Role in Immunomodulation: an Updated Systematic Review The Open Immunology Journal, 2009, 2, 9-41 9 Open Access Histamine, Histamine Receptors, and their Role in Immunomodulation: An Updated Systematic Review Mohammad Shahid*,1, Trivendra Tripathi2, Farrukh Sobia1, Shagufta Moin2, Mashiatullah Siddiqui2 and Rahat Ali Khan3 1Section of Immunology and Molecular Biology, Department of Microbiology, 2Department of Biochemistry, and 3Department of Pharmacology, Faculty of Medicine, Jawaharlal Nehru Medical College & Hospital, Aligarh Muslim University, Aligarh-202002, U.P., India Abstract: Histamine, a biological amine, is considered as a principle mediator of many pathological processes regulating several essential events in allergies and autoimmune diseases. It stimulates different biological activities through differen- tial expression of four types of histamine receptors (H1R, H2R, H3R and H4R) on secretion by effector cells (mast cells and basophils) through various immunological or non-immunological stimuli. Since H4R has been discovered very re- cently and there is paucity of comprehensive literature covering new histamine receptors, their antagonists/agonists, and role in immune regulation and immunomodulation, we tried to update the current aspects and fill the gap in existing litera- ture. This review will highlight the biological and pharmacological characterization of histamine, histamine receptors, their antagonists/agonists, and implications in immune regulation and immunomodulation. Keywords: Histamine, histamine receptors, H4-receptor, antagonists, agonists, immunomodulation. I. INTRODUCTION derivatives. For this noble research on antihistamines and curare, Bovet was awarded the Nobel Prize in 1957 [8]. It In historical evolution, histamine (biogenic amine) is was being documented that histamine played an important probably one of the most important phlogistic ancient media- role as a mediator of allergic reactions indicated by a series tor, and even one of the most intensely studied molecules in of compounds with antihistamine activity which protected biological systems which have been using histamine, guinea pigs from anaphylaxis. However, the clinical use of catecholamines and other chemical mediators to communi- these compounds in humans was precluded due to their tox- cate among cells [1]. Histamine was synthesized in 1907 and ™ icity [9]. The first antihistamine, Antergan (phenben- characterized in 1910 as a substance (“beta-1”) [2], owing to zamine, RP 2339) was being used in humans [10], but this its significant competence to constrict guinea pig ileum, and ™ compound was subsequently replaced by Neoantergan its cogent vasodepressor action. However, it took 17 years to (mepyramine, pyrilamine, RP 2786), which is still in use to demonstrate its presence in normal tissues [3]. The relation counteract the uncomfortable effects of histamine release in between histamine and anaphylactic reactions was made the skin. Many other antihistamines such as diphenhy- rapidly in 1929, and was identified as a mediator of anaphy- ™ dramine (Benadryl ), tripelennamine, chlorpheniramine and lactic reactions in 1932 [4, 5], whereas its connection to mast promethazine are also used in similar manner to counteract cells was not made until 1952 [6], and also its connection to the adverse effects of histamine [8]. Subsequently, after basophils in 1972 [7]. The search for compounds being po- 1945, these antihistamines were widely used in the treatment tent to neutralize the pathological effects of histamine began of various allergic diseases such as hay fever, urticaria, and at the Pasteur Institute in Paris during the 1930s, and these allergic rhinitis. However, the side effects were not uncom- compounds were found to partially block the effects of his- mon and the sedation was a drawback to their use. A very tamine based on the ethylenediamine structure. The first an- few side effects were put to their good use; therefore, some tihistamine compound was the adrenolytic benzodioxan, ™ antihistamines such as cyclizine (Marzine ) and diphenhy- piperoxan (933F), reported by Ungar, Parrot and Bovet in dramine in the form of its 8-chlorotheophyllinate (Drama- 1937 and was shown to block the effect of histamine on the ™ mine ) are being used as an antiemetics for travel sickness guinea-pig ileum [8]. It followed shortly by the report of [8]. By 1950 there were only 20 compounds clinically avail- Bovet and Staub [9] that structurally related to aryl ethers able to block the effects of histamine [1], but advances in such as the thymol ether (929F) [8]. The latter antihistamine histamine receptors (HRs) ligands have ever attracted many compound proved to be highly toxic for clinical develop- researchers for pharmaceutical developments and are still ment; however, the replacement of ether oxygen by an amino highly topical [11]. group led to the search of aniline ethylene diamine Histamine (2-(imidazol-4-yl) ethylamine) is one of the monoamines and was coined after the Greek word for tissue *Address correspondence to this author at the Department of Microbiology, histos, with the broadest spectrum of activities in various JN Medical College & Hospital, Aligarh Muslim University, Aligarh-202 physiological and pathological conditions including the cell 002, U.P., India; Tel: +91-571-2720382; Fax: +91-571-2720382; proliferation, differentiation, hematopoiesis, embryonic de- E-mail: [email protected]; [email protected] velopment, regeneration, wound healing, aminergic neuro- 1874-2262/09 2009 Bentham Open 10 The Open Immunology Journal, 2009, Volume 2 Shahid et al. transmission and numerous brain functions (sleep/noci- parietal cells, mast cells(~3 pg/cell histamine), and baso- ception, food intake and aggressive behavior), secretion of phils(~1 pg/cell histamine). Histamine has an important role pituitary hormones, regulation of gastrointestinal and circu- in human health, and exerting its diverse biologic effects by latory functions, cardiovascular system (vasodilatation and 4 types of receptors [1, 13, 20-22]. Histamine is also pro- blood pressure reduction), as well as inflammatory reactions, duced by enterochromaffin-like cells (ECL) in the stomach modulation of the immune response, energy of endocrine and plays an important role in secretion of gastric acid [14]. and homeostasis [1, 12-18]. It is being documented by sev- Only basophils and mast cells can store the amine in specific eral studies which highlighted the evidence of histamine that granules, in the hematopoietic system, where histamine is it elicits immune-modulatory and pro-inflammatory effects closely associated with anionic proteoglycans heparin (in by the differential expression of histamine receptors (H1R, mast cells) and chondroitin-4-sulfate (in basophils). In this H2R, H3R, and H4R) that is easily modulated the diverse specific form, histamine can be released in large amounts effects of histamine on immune regulation and distinct intra- during degranulation in response to various immunological cellular signals. All these four receptors are members of the (immunoglobulin E, or cytokines) or non-immunological 7-transmembrane (heptahelical) spanning family of recep- (compound 48/80, calcium ionophore, mastoparin, substance tors, are G protein-coupled (GPCR), are expressed on vari- P, opioids, or hypo-osmolar solutions) stimuli [14]. Hista- ous histamine responsive target tissues and cells and suggest mine synthesis in Golgi apparatus can be inhibited by - an important critical role of histamine in immunomodulation fluoromethylhistidin [23]. and allergic diseases [1, 8, 11-14]. Recently, many myeloid and lymphoid cell types that do In the present review, we will discuss biology of hista- not store histamine show more HDC activity and are capable mine including synthesis, regulation and metabolism; hista- of synthesis of high amounts of histamine [24]. This so mine receptors including H1-, H2-, H3-, and H4-receptors called “neo synthesized histamine,” has been shown in vari- and their cellular distribution, functional characterization, ous cells, including hematopoietic progenitors, macrophages, structural biology, and signaling mechanisms; non-classical neutrophils, platelets, dendritic cells (DCs) and T cells [14, histamine-binding sites such as cytochrome P450; and his- 25-28]. Histamine synthesis in non-mast cells was first con- tamine transporters; as well as immune regulation by hista- firmed using W/WV mice, which genetically lack mature mast mine in immunomodulation and allergic inflammation; ef- cells, upon stimulation with a phorbol ester [29]. HDC activ- fects of histamine in immune cells in respect to allergic dis- ity is demonstrated in vitro through cytokines, such as IL-1, eases; implication of histamine on cytokines production; IL-3, IL-12, IL- 18, GM-CSF, macrophage-colony stimulat- significance of histamine in autoimmunity and allergic dis- ing factor, TNF-, and calcium ionophore [30, 31]. Histidine eases and also in malignancies; and finally the relation of decarboxylase (HDC) activity has been modulated in condi- histamine-cytokine during hematopoiesis. tions such as LPS stimulation, inflammation, infection, and graft rejection, in vivo [32]. II. BIOLOGY OF HISTAMINE It is being demonstrated that the generation of HDC- Histamine exhibits two main important basic functionali- knockout mice provides histamine-free system and it is more ties such as primary aliphatic amine (pKa1 9.4) and imidazole beneficial to study the role of endogenous histamine in a (pKa2 5.8). These make the monocation
Recommended publications
  • Neurotransmitter Resource Guide
    NEUROTRANSMITTER RESOURCE GUIDE Science + Insight doctorsdata.com Doctor’s Data, Inc. Neurotransmitter RESOURCE GUIDE Table of Contents Sample Report Sample Report ........................................................................................................................................................................... 1 Analyte Considerations Phenylethylamine (B-phenylethylamine or PEA) ................................................................................................. 1 Tyrosine .......................................................................................................................................................................................... 3 Tyramine ........................................................................................................................................................................................4 Dopamine .....................................................................................................................................................................................6 3, 4-Dihydroxyphenylacetic Acid (DOPAC) ............................................................................................................... 7 3-Methoxytyramine (3-MT) ............................................................................................................................................... 9 Norepinephrine ........................................................................................................................................................................
    [Show full text]
  • TABLE 1 Studies of Antagonist Activity in Constitutively Active
    TABLE 1 Studies of antagonist activity in constitutively active receptors systems shown to demonstrate inverse agonism for at least one ligand Targets are natural Gs and constitutively active mutants (CAM) of GPCRs. Of 380 antagonists, 85% of the ligands demonstrate inverse agonism. Receptor Neutral Antagonist Inverse Agonist Reference Human β2-adrenergic Dichloroisoproterenol, pindolol, labetolol, timolol, Chidiac et al., 1996; Azzi et alprenolol, propranolol, ICI 118,551, cyanopindolol al., 2001 Turkey erythrocyte β-adrenergic Propranolol, pindolol Gotze et al., 1994 Human β2-adrenergic (CAM) Propranolol Betaxolol, ICI 118,551, sotalol, timolol Samama et al., 1994; Stevens and Milligan, 1998 Human/guinea pig β1-adrenergic Atenolol, propranolol Mewes et al., 1993 Human β1-adrenergic Carvedilol CGP20712A, metoprolol, bisoprolol Engelhardt et al., 2001 Rat α2D-adrenergic Rauwolscine, yohimbine, WB 4101, idazoxan, Tian et al., 1994 phentolamine, Human α2A-adrenergic Napthazoline, Rauwolscine, idazoxan, altipamezole, levomedetomidine, Jansson et al., 1998; Pauwels MPV-2088 (–)RX811059, RX 831003 et al., 2002 Human α2C-adrenergic RX821002, yohimbine Cayla et al., 1999 Human α2D-adrenergic Prazosin McCune et al., 2000 Rat α2-adrenoceptor MK912 RX821002 Murrin et al., 2000 Porcine α2A adrenoceptor (CAM- Idazoxan Rauwolscine, yohimbine, RX821002, MK912, Wade et al., 2001 T373K) phentolamine Human α2A-adrenoceptor (CAM) Dexefaroxan, (+)RX811059, (–)RX811059, RS15385, yohimbine, Pauwels et al., 2000 atipamezole fluparoxan, WB 4101 Hamster α1B-adrenergic
    [Show full text]
  • Human Histamine H2 Receptor, Frozen Cells Product No.: ES-391-AF
    TECHNICAL AequoZen® DATA SHEET Research use only. Not for use in diagnostic procedures. You are authorized to utilize these frozen cell preparations one time only. Any attempt to transfer, re-use, or propagate these cells is expressly unauthorized and a violation of the product terms and conditions of sale. Human Histamine H2 Receptor, Frozen Cells Product No.: ES-391-AF Lot No.: 2562845 Material Provided Cells: 1 x 1 mL frozen aliquot Format: ~10 x 106 cells/mL in Ham’s F12, 10% FBS with 10 % DMSO Product Information Cellular Background: CHO-K1 Parental Frozen Cells (control): A19 (replaced with Cat # ES-000-A2F) Frozen Cells Info: Frozen recombinant, CHO-K1 cells expressing mitochondrially- targeted Aequorin, Gα16 and the human Histamine H2 receptor. DNA Sequence: Identical to coding sequence of GenBank NM_022304.2. Corresponding Protein Sequence: Identical to GenBank NP_071640.1. Storage Conditions: Store in liquid nitrogen (vapor phase) immediately upon receipt, or maximum 15 days at -80°C. AequoZen® is designed for single use only. Do not refreeze. Quality Control ® EC50 for a reference agonist is determined using an AequoScreen assay (Figure 1). Mycoplasma test is performed using MycoAlert® Mycoplasma detection kit. We certify that these results meet our quality release criteria. Amthamine dihydrobromide (EC50): 6.9 nM Mycoplasma: This cell line tested negative for Mycoplasma. TDS-ES-391-AF-04 Page 1 of 5 Recommended Thawing Conditions and Handling of Frozen Cells Carefully follow instructions below to obtain the expected results. Most Frozen cells are intended to be assayed immediately upon thawing. Exceptionally, where specified, some frozen cell products require an overnight incubation in Cell Medium to enable them to perform optimally.
    [Show full text]
  • The Histamine H4 Receptor: a Novel Target for Safe Anti-Inflammatory
    GASTRO ISSN 2377-8369 Open Journal http://dx.doi.org/10.17140/GOJ-1-103 Review The Histamine H4 Receptor: A Novel Target *Corresponding author Maristella Adami, PhD for Safe Anti-inflammatory Drugs? Department of Neuroscience University of Parma Via Volturno 39 43125 Parma Italy * 1 Tel. +39 0521 903943 Maristella Adami and Gabriella Coruzzi Fax: +39 0521 903852 E-mail: [email protected] Department of Neuroscience, University of Parma, Via Volturno 39, 43125 Parma, Italy Volume 1 : Issue 1 1retired Article Ref. #: 1000GOJ1103 Article History Received: May 30th, 2014 ABSTRACT Accepted: June 12th, 2014 th Published: July 16 , 2014 The functional role of histamine H4 receptors (H4Rs) in the Gastrointestinal (GI) tract is reviewed, with particular reference to their involvement in the regulation of gastric mucosal defense and inflammation. 4H Rs have been detected in different cell types of the gut, including Citation immune cells, paracrine cells, endocrine cells and neurons, from different animal species and Adami M, Coruzzi G. The Histamine H4 Receptor: a novel target for safe anti- humans; moreover, H4R expression was reported to be altered in some pathological conditions, inflammatory drugs?. Gastro Open J. such as colitis and cancer. Functional studies have demonstrated protective effects of H4R an- 2014; 1(1): 7-12. doi: 10.17140/GOJ- tagonists in several experimental models of gastric mucosal damage and intestinal inflamma- 1-103 tion, suggesting a potential therapeutic role of drugs targeting this new receptor subtype in GI disorders, such as allergic enteropathy, Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS) and cancer. KEYWORDS: Histamine H4 receptor; Stomach; Intestine.
    [Show full text]
  • From Inverse Agonism to 'Paradoxical Pharmacology' Richard A
    International Congress Series 1249 (2003) 27-37 From inverse agonism to 'Paradoxical Pharmacology' Richard A. Bond*, Kenda L.J. Evans, Zsirzsanna Callaerts-Vegh Department of Pharmacological and Pharmaceutical Sciences, University of Houston, 521 Science and Research Bldg 2, 4800 Caltioun, Houston, TX 77204-5037, USA Received 16 April 2003; accepted 16 April 2003 Abstract The constitutive or spontaneous activity of G protein-coupled receptors (GPCRs) and compounds acting as inverse agonists is a recent but well-established phenomenon. Dozens of receptor subtypes for numerous neurotransmitters and hormones have been shown to posses this property. However, do to the apparently low percentage of receptors in the spontaneously active state, the physiologic relevance of these findings remains questionable. The possibility that the reciprocal nature of the effects of agonists and inverse agonists may extend to cellular signaling is discussed, and that this may account for the beneficial effects of certain p-adrenoceptor inverse agonists in the treatment of heart failure. © 2003 Elsevier Science B.V. All rights reserved. Keywords. Inverse agonism; GPCR; Paradoxical pharmacology 1. Brief history of inverse agonism at G protein-coupled receptors For approximately three-quarters of a century, ligands that interacted with G protein- coupled receptors (GPCRs) were classified either as agonists or antagonists. Receptors were thought to exist in a single quiescent state that could only induce cellular signaling upon agonist binding to the receptor to produce an activated state of the receptor. In this model, antagonists had no cellular signaling ability on their own, but did bind to the receptor and prevented agonists from being able to bind and activate the receptor.
    [Show full text]
  • Diphenhydramine Hydrochloride (CASRN 147-24-0) in F344/N Rats
    NATIONAL TOXICOLOGY PROGRAM Technical Report Series No. 355 TOXICOLOGY AND CARCINOGENESIS STUDIES OF DIPHENHYDRAMINE HYDROCHLORIDE (CAS NO. 147-24-0) IN F344/N RATS AND B6C3F1 MICE (FEED STUDIES) LJ.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health NTP ‘TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF DIPHENHYDRAMINE HYDROCHLORIDE (CAS NO. 147-24-0) IN F344/N RATS AND B6C3F1 MICE (FEED STUDIES) R. Melnick, Ph.D., Study Scientist NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709 September 1989 NTP TR 355 NIH Publication No. 89-2810 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health CONTENTS PAGE ABSTRACT ................................................................ 3 EXPLANATION OF LEVELS OF EVIDENCE OF CARCINOGENIC ACTIVITY .................. 6 CONTRIBUTORS ............................................................ 7 PEERREVIEWPANEL ........................................................ 8 SUMMARY OF PEER REVIEW COMMENTS ......................................... 9 I. INTRODUCTION ........................................................ 11 I1. MATERIALS AND METHODS .............................................. 21 III. RESULTS ............................................................. 35 RATS ............................................................. 36 MICE ............................................................. 45 GENETIC TOXICOLOGY ............................................... 53 IV.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub
    US 2010O221245A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub. Date: Sep. 2, 2010 (54) TOPICAL SKIN CARE COMPOSITION Publication Classification (51) Int. Cl. (76) Inventor: Audrey Kunin, Mission Hills, KS A 6LX 39/395 (2006.01) (US) A6II 3L/235 (2006.01) A638/16 (2006.01) Correspondence Address: (52) U.S. Cl. ......................... 424/133.1: 514/533: 514/12 HUSCH BLACKWELL SANDERS LLP (57) ABSTRACT 4801 Main Street, Suite 1000 - KANSAS CITY, MO 64112 (US) The present invention is directed to a topical skin care com position. The composition has the unique ability to treat acne without drying out the user's skin. In particular, the compo (21) Appl. No.: 12/395,251 sition includes a base, an antibacterial agent, at least one anti-inflammatory agent, and at least one antioxidant. The (22) Filed: Feb. 27, 2009 antibacterial agent may be benzoyl peroxide. US 2010/0221 245 A1 Sep. 2, 2010 TOPCAL SKIN CARE COMPOSITION stay of acne treatment since the 1950s. Skin irritation is the most common side effect of benzoyl peroxide and other anti BACKGROUND OF THE INVENTION biotic usage. Some treatments can be severe and can leave the 0001. The present invention generally relates to composi user's skin excessively dry. Excessive use of some acne prod tions and methods for producing topical skin care. Acne Vul ucts may cause redness, dryness of the face, and can actually garis, or acne, is a common skin disease that is prevalent in lead to more acne. Therefore, it would be beneficial to provide teenagers and young adults.
    [Show full text]
  • Pitolisant (Wakix) Reference Number: CP.PMN.221 Effective Date: 03.01.20 Last Review Date: 02.21 Line of Business: Commercial, HIM, Medicaid Revision Log
    Clinical Policy: Pitolisant (Wakix) Reference Number: CP.PMN.221 Effective Date: 03.01.20 Last Review Date: 02.21 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description ® Wakix (pitolisant) is a selective histamine 3 (H3) receptor antagonist/inverse agonist. FDA Approved Indication(s) Wakix is indicated for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Wakix is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Narcolepsy with Cataplexy (must meet all): 1. Diagnosis of narcolepsy with cataplexy; 2. Prescribed by or in consultation with a neurologist or sleep medicine specialist; 3. Age ≥ 18 years; 4. Failure of 2 of the following antidepressants, each used for ≥ 1 month, unless member’s age is ≥ 65, clinically significant adverse effects are experienced, or all are contraindicated: venlafaxine, fluoxetine, atomoxetine, clomipramine, protriptyline; 5. Dose does not exceed 35.6 mg (two 17.8 mg tablets) per day. Approval duration: Medicaid/HIM – 12 months Commercial – Length of Benefit B. Narcolepsy with Excessive Daytime Sleepiness (must meet all): 1. Diagnosis of narcolepsy with EDS; 2. Prescribed by or in consultation with a neurologist or sleep medicine specialist; 3. Age ≥ 18 years; 4. Failure of a 1-month trial of one of the following central nervous system (CNS) stimulants at up to maximally indicated doses, unless clinically significant adverse effects are experienced or all are contraindicated: amphetamine immediate-release (IR), amphetamine, dextroamphetamine IR, dextroamphetamine, methylphenidate IR; *Prior authorization may be required for CNS stimulants Page 1 of 6 CLINICAL POLICY Pitolisant 5.
    [Show full text]
  • Chapter 2 Molecular Aspects of Histamine Receptors
    VU Research Portal Shedding Light on the Histamine H3 Receptor Mocking, T.A.M. 2020 document version Publisher's PDF, also known as Version of record Link to publication in VU Research Portal citation for published version (APA) Mocking, T. A. M. (2020). Shedding Light on the Histamine H3 Receptor: Photopharmacology and bioluminescent assays to study GPCRs. General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. E-mail address: [email protected] Download date: 06. Oct. 2021 Chapter 2 Molecular aspects of histamine receptors Histamine mediates a multitude of physiological effects in the human body by activating four histamine receptor subtypes. Histamine receptors have proven to be promising drug targets in the treatment of a variety of diseases, including hay fever, gastric ulcers, inflammatory and neuropathological diseases. In this chapter the molecular aspects of histamine receptors are described, including expression profile, intracellular signaling, and how histamine receptor activity can be attenuated by ligands targeting the histamine receptor binding sites.
    [Show full text]
  • Role of Dietary Histidine in the Prevention of Obesity and Metabolic Syndrome
    Open access Editorial Open Heart: first published as 10.1136/openhrt-2017-000676 on 1 July 2018. Downloaded from Role of dietary histidine in the prevention of obesity and metabolic syndrome James J DiNicolantonio,1 Mark F McCarty,2 James H OKeefe 1 To cite: DiNicolantonio JJ, HISTIDINE SUPPLEMENTATION AMELIORATES histidine dose dependently increases hypo- McCarty MF, OKeefe JH. Role of METABOLIC SYNDROME thalamic levels of histamine as well as hypo- dietary histidine in the prevention of obesity and A recent Chinese supplementation study, in thalamic activity of histidine decarboxylase, metabolic syndrome. Open Heart which obese middle-aged women diagnosed the enzyme which converts histidine to hista- 10 2018;5:e000676. doi:10.1136/ with metabolic syndrome received 12 weeks mine. Such administration also inhibits food openhrt-2017-000676 of supplemental histidine (2 g, twice daily) or consumption—an effect that is blocked in matching placebo, achieved remarkable find- animals pretreated with an irreversible inhib- 1 Accepted 24 April 2018 ings. Insulin sensitivity improved significantly itor of histidine decarboxylase. in the histidine-supplemented subjects, and Neuronal histamine release in the hypo- this may have been partially attributable to thalamus is subject to feedback regulation loss of body fat. Body mass index (BMI), waist by presynaptic H3 receptors. In rodent circumference and body fat declined in the studies, antagonists and inverse agonists for histidine-supplemented group relative to the these receptors have been shown to mark- placebo group; the average fat loss in the histi- edly amplify hypothalamic histamine levels, dine group was a robust 2.71 kg. Markers of suppress feeding, decrease body weight and systemic inflammation such as serum tumour enhance metabolic rate.11–15 Such agents may necrosis factor-alpha (TNF-α) and inter- have clinical potential for managing obesity.
    [Show full text]
  • Mol.116.105981.Full.Pdf
    Molecular Pharmacology Fast Forward. Published on September 13, 2016 as DOI: 10.1124/mol.116.105981 This article has not been copyedited and formatted. The final version may differ from this version. MOL #105981 CURRENT KNOWLEDGE AND PERSPECTIVES FOR HISTAMINE H1 AND H2 RECEPTOR PHARMACOLOGY. FUNCTIONAL SELECTIVITY, RECEPTOR CROSSTALK AND REPOSITIONING OF CLASSIC HISTAMINERGIC LIGANDS. Downloaded from Federico Monczor and Natalia Fernandez. Instituto de Investigaciones Farmacológicas, ININFA. Universidad de Buenos Aires—Consejo molpharm.aspetjournals.org Nacional de Investigaciones Científicas y Técnicas, CONICET. Buenos Aires, Argentina. at ASPET Journals on September 28, 2021 1 Molecular Pharmacology Fast Forward. Published on September 13, 2016 as DOI: 10.1124/mol.116.105981 This article has not been copyedited and formatted. The final version may differ from this version. MOL #105981 Running title: Current and perspectives for histamine receptors pharmacology. Corresponding author: Federico Monczor. Laboratorio de Farmacología de Receptores. Instituto de Investigaciones Farmacológicas, ININFA. Universidad de Buenos Aires—Consejo Nacional de Investigaciones Científicas y Técnicas, CONICET. Junin 956 (1113) Buenos Aires, Argentina. Tel:+54-11-5287-4856. e-mail: [email protected]. Total text pages: 41 Downloaded from Tables: 2 Figures: 1 References: 125 molpharm.aspetjournals.org Abstract words: 222 Abbreviations: AML, acute myeloid leukemia; ATP, adenosine triphosphate; GTP, guanosine triphosphate; AC, adenylyl cyclase; IP, inositol
    [Show full text]
  • Histidine Decarboxylase Knockout Mice Production and Signal
    Nitric Oxide Mediates T Cell Cytokine Production and Signal Transduction in Histidine Decarboxylase Knockout Mice This information is current as Agnes Koncz, Maria Pasztoi, Mercedesz Mazan, Ferenc of October 1, 2021. Fazakas, Edit Buzas, Andras Falus and Gyorgy Nagy J Immunol 2007; 179:6613-6619; ; doi: 10.4049/jimmunol.179.10.6613 http://www.jimmunol.org/content/179/10/6613 Downloaded from References This article cites 41 articles, 8 of which you can access for free at: http://www.jimmunol.org/content/179/10/6613.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on October 1, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Nitric Oxide Mediates T Cell Cytokine Production and Signal Transduction in Histidine Decarboxylase Knockout Mice1 Agnes Koncz,*† Maria Pasztoi,* Mercedesz Mazan,* Ferenc Fazakas,‡ Edit Buzas,* Andras Falus,*§ and Gyorgy Nagy2,3*¶ Histamine is a key regulator of the immune system.
    [Show full text]